University of the Philippines
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Takeuchi, Tsutomu
APLCLLDAS, NCT03138941: Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region

Recruiting
N/A
5000
Japan, RoW
Monash University, Flinders Medical Centre, Adelaide, AUSTRALIA, St. Vincent's Hospital, Melbourne, AUSTRALIA, Royal Adelaide Hospital, Adelaide, AUSTRALIA, University of New South Wales, Sydney, AUSTRALIA, People's Hospital, Peking University Health Science Center, Beijing, CHINA, Peking University First Hospital, Beijing, CHINA, The University of Hong Kong, HONG KONG, University of Padjadjaran, Bandung, INDONESIA, Tokyo Women's Medical University, JAPAN, University of Occupational and Environmental Health, JAPAN, Keio University, JAPAN, Hanyang University Hospital for Rheumatic Diseases, REPUBLIC OF KOREA, University of Santo Tomas Hospital, Philippines, National University Hospital, Singapore, Tan Tock Seng Hospital, Chang Gung Memorial Hospital, Taichung Veterans General Hospital, Chiang Mai University Hospital, THAILAND, Middlemore Hospital, New Zealand, North Shore Hospital, Auckland, NEW ZEALAND, Auckland District Health Board, Auckland, NEW ZEALAND, Teaching Hospital Kandy, SRI LANKA, University of the Philippines, Philippines
Systemic Lupus Erythematosus
12/27
12/32
Tee, Michael
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
NCT05485584: rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19

Active, not recruiting
2
188
RoW
rSIFN-co Nasal Spray, rSIFN-co, Placebo Nasal Spray, ingredients
Sichuan Huiyang Life Science and Technology Corporation
COVID-19, SARS-CoV-2 Infection
04/23
12/24
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
APLCLLDAS, NCT03138941: Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region

Recruiting
N/A
5000
Japan, RoW
Monash University, Flinders Medical Centre, Adelaide, AUSTRALIA, St. Vincent's Hospital, Melbourne, AUSTRALIA, Royal Adelaide Hospital, Adelaide, AUSTRALIA, University of New South Wales, Sydney, AUSTRALIA, People's Hospital, Peking University Health Science Center, Beijing, CHINA, Peking University First Hospital, Beijing, CHINA, The University of Hong Kong, HONG KONG, University of Padjadjaran, Bandung, INDONESIA, Tokyo Women's Medical University, JAPAN, University of Occupational and Environmental Health, JAPAN, Keio University, JAPAN, Hanyang University Hospital for Rheumatic Diseases, REPUBLIC OF KOREA, University of Santo Tomas Hospital, Philippines, National University Hospital, Singapore, Tan Tock Seng Hospital, Chang Gung Memorial Hospital, Taichung Veterans General Hospital, Chiang Mai University Hospital, THAILAND, Middlemore Hospital, New Zealand, North Shore Hospital, Auckland, NEW ZEALAND, Auckland District Health Board, Auckland, NEW ZEALAND, Teaching Hospital Kandy, SRI LANKA, University of the Philippines, Philippines
Systemic Lupus Erythematosus
12/27
12/32

Download Options